aTyr Pharma Inc. Common Stock (ATYR)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach aTyr Pharma as a Graham-style investor, and the first question is whether there is a durable business beneath the story. The answer here is not yet. It is a clinical-stage biotech with 58 employees, no approved product, and a lead candidate, efzofitimod, in a Phase 3 trial for pulmonary sarcoidosis. That is a binary research bet, not a moat. The filed numbers show why: in fiscal 2025, the year ended 2025-12-31, revenue was $190,000 and net loss was $74.1 million, or $0.80 per diluted share. In fiscal 2024, the year ended 2024-12-31, revenue was $235,000 and net loss was $64.0 million, or $0.86 per diluted share. In fiscal 2023, the year ended 2023-12-31, revenue was $353,000 and net loss was $50.4 million, or $0.94 per diluted share. The losses are persistent and large relative to the $19.7 million market cap at the 2026-10-13 close. FairStock's trailing free cash flow is -$54.8 million, a -278% FCF yield, so cash burn is enormous. FairStock also shows a negative P/E of -0.32, P/B of 0.40, ROE of -98.68%, Piotroski F-Score of 1/9, and Altman Z-Score of -12.47. A low price-to-book ratio can tempt a bargain hunter, but book value is only meaningful if the company can survive and finance itself without destroying shareholders. The computed Lynch category is none, because it lost money in each of the last four years. Without profits, a clear moat, or a margin of safety, this is speculation on trial data, not a conservative value investment.

In plain English: aTyr Pharma is a small medical research company working on new treatments for fibrosis and inflammation; its lead drug is still being tested in people. The business looks weak financially because it has almost no revenue and loses tens of millions of dollars a year. The $0.20 share price may look low compared with its accounting value, but that apparent cheapness reflects a very risky company with no profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer